pralatrexate + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a **combination chemotherapy regimen** comprised of pralatrexate, cyclophosphamide, doxorubicin, vincristine, and prednisone. The regimen is designed for the treatment of aggressive lymphomas, particularly peripheral T-cell lymphomas (PTCL). Each component has a distinct mechanism of action: - **Pralatrexate**: An antifolate that inhibits dihydrofolate reductase, disrupting DNA synthesis. - **Cyclophosphamide**: An alkylating agent causing DNA cross-linking and inhibition of cell replication. - **Doxorubicin**: An anthracycline that intercalates DNA and inhibits topoisomerase II, leading to DNA breaks. - **Vincristine**: A vinca alkaloid that binds tubulin, inhibiting microtubule formation and mitosis. - **Prednisone**: A synthetic corticosteroid with anti-inflammatory and lympholytic effects, leading to apoptosis of sensitive cells. This combination aims to attack malignant lymphocytes through **multiple complementary mechanisms**, enhancing efficacy and minimizing resistance. It is used in clinical trials as an alternative or modification to standard CHOP chemotherapy, predominantly for aggressive or relapsed/refractory T-cell/non-Hodgkin lymphomas[1][3][5][7].